※一部利用できない機能があります
| 1.
論文 |
論文
|
Mizukoshi, Eishiro ; Fushimi, Kazumi ; Arai, Kuniaki ; Yamashita, Tatsuya ; Honda, Masao ; Kaneko, Shuichi
概要:
Background & Aims: Chondroitin-glucuronate C5-epimerase is an enzyme that converts D-glucuronic acid to L-iduronic acid
…
residues in dermatan sulphate biosynthesis. It is also identified to be a tumour-associated antigen recognized by cytotoxic T cells (CTLs) and its enhanced expression in many cancers has been reported. In the present study, we investigated the usefulness of this molecule as an immunotherapeutic target in hepatocellular carcinoma (HCC). Methods: The expression of chondroitin-glucuronate C5-epimerase in hepatoma cell lines and HCC tissues was confirmed by immunofluorescence and immunohistochemical analysis. CTL responses were investigated by several immunological techniques using peripheral blood mononuclear cells (PBMCs) or tumour-infiltrating lymphocytes. To determine the safety of immunotherapy using chondroitin-glucuronate C5-epimerase-derived peptide, 12 patients with HCC were administered s.c. vaccinations of the peptides and analysed. Results: Chondroitin-glucuronate C5-epimerase was expressed in HCC cell lines and human tissues including alpha-foetoprotein (AFP)-negative individuals. Chondroitin-glucuronate C5-epimerase-specific CTLs could be generated by stimulating PBMCs of HCC patients with peptides and they showed cytotoxicity against HCC cells expressing the protein. The frequency of CTL precursors investigated by enzyme-linked immunospot (ELISPOT) assay was 0-34 cells/3 × 10 5 PBMCs and the infiltration of interferon-gamma-producing CTLs into the tumour site was confirmed. In the vaccination study, no severe adverse events were observed and the peptide-specific CTLs were induced in 4 of 12 patients tested. Conclusions: Chondroitin-glucuronate C5-epimerase is a potential candidate for tumour antigen with immunogenicity and the peptides derived from this antigen could be useful in HCC immunotherapy. © 2012 John Wiley & Sons A/S.
続きを見る
|
||||
| 2.
論文 |
論文
|
Kitahara, Masaaki ; Mizukoshi, Eishiro ; Nakamoto, Yasunari ; Mukaida, Naofumi ; Matsushima, Kouji ; Kaneko, Shuichi
概要:
Background & aims Immunotherapy using dendritic cells (DCs) is a promising cancer therapy. The success of this therapy d
…
epends on the function of induced DCs. However, there has been no consensus on optimal conditions for DC preparation in vitro for immunotherapy of hepatocellular carcinoma (HCC) patients. To address relevant issues, we evaluated the procedures to induce DCs that efficiently function in hepatitis C virus (HCV)-related HCC. Methods We studied immunological data from 14 HCC patients. The DC preparation and the surface markers were assessed by flow cytometric analysis. Four different additional activation stimuli (Method I, medium alone; Method II, with OK-432; Method III, with IL-1β + IL-6 + TNF-α; Method IV, with IL-1β + IL-6 + TNF-α + PGE2) were tested and the functions of DCs were confirmed by examination of the ability of phagocytosis, cytokine production and allogeneic mixed lymphocyte reaction (MLR). Results The numbers of DCs induced and their cytokine production ability were not different between healthy controls and HCC patients. T-cell stimulatory activity of DCs in MLR was significantly lower in HCC patients than in healthy controls. The maturation of DCs with OK-432 boosted production of cytokines and chemokines, such as IL-2, IL-12p70, IFN-γ, TNF-α, IL-13 and MIP1α, and restored T-cell stimulatory activity of DCs in MLR. Conclusions The clinically approved compound OK-432 is a candidate for highly immunocompetent DC preparation and may be considered as a key drug for immunotherapy of HCV-related HCC patients. © 2014 Published by Elsevier B.V.
続きを見る
|
||||
| 3.
論文 |
論文
|
Mizukoshi, Eishiro ; Yamashita, Tatsuya ; Arai, Kuniaki ; Terashima, Takeshi ; Kitahara, Masaaki ; Nakagawa, Hidetoshi ; Iida, Noriho ; Fushimi, Kazumi ; Kaneko, Shuichi
概要:
Hepatic arterial infusion chemotherapy (HAIC) has been employed as an alternative therapy to sorafenib for the patients
…
with advanced hepatocellular carcinoma (HCC). In this study, we performed a comparative analysis of various immune cell responses including tumor-associated antigen (TAA)-specific T cells, regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs) in advanced HCC patients treated with HAIC. Thirty-six HCC patients were examined in the study. Interferon gamma enzyme-linked immunospot assays were performed to examine the frequency of TAA-specific T cells. The frequencies of Tregs and MDSCs were examined by multicolor fluorescence-activated cell sorting analysis. The treatment with HAIC using interferon (IFN)/5-fluorouracil (FU) or IFN/FU + cisplatin modulated the frequencies of various immune cells. In 22.2 % of patients, the frequency of TAA-specific T cells increased after HAIC. Although the frequency of Tregs decreased after HAIC, it was not associated with the prognosis of patients. An analysis of prognostic factors for overall survival identified diameter of the tumor (<3.0 cm), absence of major portal vein invasion, absence of distant metastasis, Union Internationale Contre Le Cancer tumor lymph node metastasis stage (I or II), neutrophil lymphocytic ratio (<2.1) and the frequency of MDSCs (<30.5 %) as factors that prolonged overall survival time after HAIC. Even in the group adjusted with progressive levels of tumors, patients with a low frequency of MDSCs had a significantly longer overall survival time. In conclusion, the frequency of MDSCs before the treatment is a prognostic factor in HAIC against HCC. © 2016 Springer-Verlag Berlin Heidelberg
続きを見る
|
||||
| 4.
論文 |
論文
|
Mizukoshi, Eishiro ; Nakagawa, Hidetoshi ; Kitahara, Masaaki ; Yamashita, Tatsuya ; Arai, Kuniaki ; Sunagozaka, Hajime ; Iida, Noriho ; Fushimi, Kazumi ; Kaneko, Shuichi
概要:
Multidrug resistance-associated protein 3 (MRP3) is a carrier-type transport protein belonging to the ABC transporters.
…
In this study, we investigated the safety and immunogenicity of a MRP3-derived peptide (MRP3765) as a vaccine and characterized the MRP3-specific T cell responses induced. Twelve hepatocellular carcinoma (HCC) patients treated with hepatic arterial infusion chemotherapy (HAIC) were enrolled. The MRP3-derived peptide was emulsified in incomplete Freund's adjuvant and administered via subcutaneous immunization three times weekly. No serious adverse drug reactions to the peptide vaccine were observed, and the vaccination was well tolerated. The vaccination induced MRP3-specific immunity in 72.7% of the patients. In a phenotypic analysis, the largest post-vaccinated increase in MRP3-specific T cells was due to an increase in cells with the effector memory phenotype. Among the 12 patients, one patient showed a partial response, nine showed a stable disease, and two showed a progressive disease. The median overall survival time was 14.0 months. In conclusion, the safety, effects of immune boosting, and possible prolongation of overall survival by the MRP3-derived peptide demonstrate the potential of the peptide to provide clinical benefit in HCC patients. © 2015.
続きを見る
|
||||
| 5.
論文 |
論文
|
Mizukoshi, Eishiro ; Kaneko, Shuichi
概要:
Hepatocellular carcinoma (HCC) is the sixth most common type of cancer globally. Although many different kinds of treatm
…
ent are performed for HCC according to the practical guidelines, the prognosis of patients is not still satisfactory because the effects of treatments are limited for advanced tumors and the recurrence rate of HCC, even in early stages, is very high. Therefore, immunotherapy is highly anticipated as a new treatment method for HCC. For the development of a new HCC therapy, we attempted to establish immunotherapy using dendritic cells (DCs) and peptide vaccine. In several clinical trials that we performed, we confirmed that the immunotherapy was safe and well-tolerated by HCC patients. We observed that DC therapy prolonged the recurrence-free survival of patients compared with that of patients without DC infusion, as well as observing the radiological anti-tumor effect in HCC patients with peptide vaccine. In this chapter, we summarize the results of previous studies using DC and peptide vaccine, including our own data, and describe the prospects of immunotherapy for HCC. © 2015, Springer Japan. All rights reserved.<br />[Book Chapter]
続きを見る
|
||||
| 6.
論文 |
論文
|
Nakamoto, Yasunari ; Kaneko, Shuichi ; Fan, Hong ; Momoi, Takashi ; Tsutsui, Hiroko ; Nakanishi, Kenji ; Kobayashi, Kenichi ; Suda, Takashi
概要:
金沢大学がん研究所がん病態制御<br />A persistent immune response to hepatitis viruses is a well-recognized risk factor for hepatocellul
…
ar carcinoma. However, the molecular and cellular basis for the procarcinogenic potential of the immune response is not well defined. Here, using a unique animal model of chronic hepatitis that induces hepatocellular carcinogenesis, we demonstrate that neutralization of the activity of Fas ligand prevented hepatocyte apoptosis, proliferation, liver inflammation, and the eventual development of hepatocellular carcinoma. The results indicate that Fas ligand is involved not only in direct hepatocyte killing but also in the process of inflammation and hepatocellular carcinogenesis in chronic hepatitis. This is the first demonstration that amelioration of chronic inflammation by some treatment actually caused reduction of cancer development.
続きを見る
|
||||
| 7.
論文 |
論文
|
Nakamoto, Yasunari ; Kaneko, Shuichi ; Fan, Hong ; Momoi, Takashi ; Tsutsui, Hiroko ; Nakanishi, Kenji ; Kobayashi, Kenichi ; Suda, Takashi
概要:
A persistent immune response to hepatitis viruses is a well-recognized risk factor for hepatocellular carcinoma. However, the molecular and cellular basis for the procarcinogenic potential of the immune response is not well defined.
…
Here, using a unique animal model of chronic hepatitis that induces hepatocellular carcinogenesis, we demonstrate that neutralization of the activity of Fas ligand prevented hepatocyte apoptosis, proliferation, liver inflammation, and the eventual development of hepatocellular carcinoma. The results indicate that Fas ligand is involved not only in direct hepatocyte killing but also in the process of inflammation and hepatocellular carcinogenesis in chronic hepatitis. This is the first demonstration that amelioration of chronic inflammation by some treatment actually caused reduction of cancer development.
続きを見る
|
||||
| 8.
論文 |
論文
|
金子, 周一 ; Kaneko, Shuichi
概要:
癌に対するバイオセンサー型DNAチップを作製するため、初年度は1)肝癌に関連する肝臓内の遺伝子の発現のパターンを明らかにすると同時に、その情報を用いてDNAチップを作製すること、2)このチップの情報を微少電極集積型バイオセンサーにて読みとる
…
技術を開発することを目的とした。2年目以降はチップの開発をさらにすすめ臨床応用をめざすことを目的とした。肝細胞癌等を用いて、DNAチップにおける解析を行った。100例におよぶ臨床材料の解析から、従来の生化学所見や病理組織では得られなかった情報が得られ、DNAチップが新たな診断法のひとつになりうる可能性を示すことが出来た(Gastroenterology 2001)。また肝癌由来培養細胞および肝癌を用いて、新たな腫瘍マーカーの可能性、および分化度を推定する診断法になる可能性を示した(Hepatology 2001a, 2001b)。serial gene expression analysis(SAGE)法を行い、包括的な遺伝子発現のプロファイルを作製し(BBRC 2000, 2001)、世界最大の肝臓発現遺伝子データベースを有することが出来た。一連の成果から、C型慢性肝炎の薬剤反応性をDNAチップで検査する方法を開発し、臨床検査試薬として平成14年に発売した。微小電極を用いて、液層における反応系を考案し、目的とする核酸の測定を可能とした(平成13年特許出願)。微小電極測定に導入するため小型のサーマルサイクラーを開発し、特許出願した(平成12年)。基盤上の微小な金属電極にDNAをスポットする装置を開発した(特許出願準備中)。これらの研究をもとに微小電極を用いた核酸測定系を開発した(特許出願準備中)。このバイオセンサー型DNA測定系は、臨床の現場で使用することを目的とし、小型で安価、かつ迅速に試料を測定できるものが作製された。<br />Development of a biosensor-type-DNA chip for the diagnosis of cancer is an objective of this research. To attain this objective, two lines of research projects were designed.For the first line of the project, we systematically examined expression profiles in the liver with various diseases including hepatocellular carcinoma. Over one hundred clinical materials were analyzed with home-made DNA chips, and the expression profile in each disease was demonstrated. This study revealed that a DNA chip analysis gives new information that cannot be obtained by routine biochemical and pathological examinations, and made the DNA chip be a new diagnostic technique, or a new tumor marker. Using serial analysis of gene expression (SAGE), over 300,000 expressed tags in the liver were obtained and deposited into databases. A DNA chip, which predicts the efficacy of drugs against chronic hepatitis C, was put on the market.Another line of the project is to make a biosensor-type-DNA chip, which can be used in routine clinical settings on site. Using microelectrodes on a chip, target nucleic acids can be measured in liquid (applied for a patent in 2001). A small-size thermal cycler for the introduction of measurement on microelectrodes was developed (applied for a patent in 2000). A DNA spotter on a microelectrode was also developed (pending for a patent). Using these successive developments, a biosensor-type-DNA chip, which is small-size, less expensive compared with former laser-detection-type DNA chips, and faster for the clinical diagnosis, was made.<br />研究課題/領域番号:11794017, 研究期間(年度):1999-2001<br />出典：「癌に対するバイオセンサー型DNAチップの開発」研究成果報告書 課題番号11794017(KAKEN：科学研究費助成事業データベース（国立情報学研究所）) 本文データは著者版報告書より作成
続きを見る
|
